$35.87
arrow_drop_up0.51%Based on the fundamental analysis of Baxter International Inc, several key indicators stand out. Firstly, the company has a healthy dividend yield of 2.83%, which indicates a consistent return for investors. Additionally, Baxter's net margin of 17.93% highlights the company's ability to generate profits from its revenue, showcasing its operational efficiency. The company's price-to-book ratio of 2.48 suggests that the stock may be undervalued relative to its book value, making it a potentially attractive investment opportunity. Furthermore, Baxter's return on assets of 3.34% and return on equity of -0.96% provide insights into the company's profitability and how efficiently it is utilizing its assets to generate earnings. In addition to these indicators, Baxter International Inc's revenue growth of 8.57% reflects the company's ability to increase its top line, indicating a healthy business performance. The company's debt-to-equity ratio of 1.7 suggests that Baxter has a moderate level of debt relative to its equity, which can be viewed as a positive sign for investors. Overall, these fundamental analysis indicators paint a picture of a company with strong financial health, profitability, and growth potential, making Baxter International Inc a promising investment opportunity in the healthcare sector.
Baxter International Inc. has been announced as a dividend of $0.29, which may attract investors seeking regular income. The company has announced that it will present at the Raymond James 45th Annual Institutional Investors Conference, which may boost investor confidence and provide new investment opportunities. The company's stock has shown a consistent upward trend in the past few weeks, indicating a potential growth in the future.
The company's stock has underperformed its competitors in some trading sessions, which could be a cause for concern for investors. The company's long-term debt to equity ratio is quite high, which could indicate financial instability in the future. The company's payout ratio is relatively high, which may suggest that the company is not generating enough profits to support its dividend payments.
Baxter International Inc. has a neutral technical rating based on various indicators. The stock is currently showing a technical buy signal with indicators such as ATR and ROC, while also having multiple hold indicators including RSI, MACD, CCI, ADX, and WILLR. However, there is also one sell indicator in the form of STOCHRSI. This mixed technical signal suggests that the stock may be experiencing some indecision in the near term, with potential for both bullish and bearish movements. Furthermore, Baxter International Inc. has a technical buy indicator count of 2 and a technical hold indicator count of 5 for the month. The company’s technical analysis also reveals a cumulative multiple of 16.2 and a score of 58 in the market category. These metrics, along with the stock’s performance in the healthcare sector, indicate that Baxter International Inc. is closely monitored and has the potential for significant movements in the coming months. Investors may want to keep a close eye on the technical indicators and market sentiment to make informed decisions about their investments in the company.
Based on the data provided, Baxter International Inc (BAX) appears to be a stable and reliable investment option in the healthcare sector. With a current price of $42.5, Baxter has shown a consistent upward trend in its stock price, with a seven-day price change percent of 0.21% and a one-month price change percent of 10.33%. The company also offers a dividend yield of 2.83% and has a strong market ownership score of 38, indicating a high level of institutional ownership. Baxter's financials, such as a market cap of $21.58B, revenue of $14.81B, and net margin of 17.93%, suggest a healthy balance sheet and profitability. In conclusion, considering Baxter International Inc's steady growth, strong market position, and attractive dividend yield, it is recommended for investors seeking a long-term investment in the healthcare sector. The company's solid financials and positive analyst forecasts, with an analyst forecast price of $48.67 and a 14.51% forecasted price change, further support its potential for continued success. However, investors should also keep an eye on factors such as the company's net income, which is currently negative at -$69M, and its return on equity of -0.96%. Overall, Baxter International Inc presents a promising investment opportunity with the potential for growth and stability in the healthcare industry.